JonesResearch upgraded Beam Therapeutics (BEAM) to Buy from Hold with a $34 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright
- Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target
- Beam Therapeutics upgraded to Outperform from Sector Perform at Scotiabank
- Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst
- Beam Therapeutics’ BEAM-302 Shows Promising Efficacy and Safety in AATD Treatment, Earning Buy Rating
Questions or Comments about the article? Write to editor@tipranks.com